Cytek Biosciences (CTKB) Change in Accured Expenses (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Change in Accured Expenses data on file, last reported at -$3.9 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 83.4% year-over-year to -$3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 32.51% YoY) and the FY2025 annual result came in at $4.0 million, up 585.92% from the prior year.
• Change in Accured Expenses declined to -$3.9 million in Q1 2026, from $4.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.6 million in Q3 2024 to a low of -$4.8 million in Q2 2024.
• A 5-year average of $438941.2 and a median of $335000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 2368.91% in 2024, down 360.86% in 2024.
• Tracing CTKB's Change in Accured Expenses over 5 years: stood at $4.6 million in 2022, then sank by 97.44% to $119000.0 in 2023, then jumped by 2368.91% to $2.9 million in 2024, then surged by 60.28% to $4.7 million in 2025, then tumbled by 182.61% to -$3.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.9 million (Q1 2026), $4.7 million (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.